 Home > Active Ingredient News > Immunology News > PsA treatment is a new era, and biologics can be expected in the future!

PsA treatment is a new era, and biologics can be expected in the future!

 Last Update: 2022-10-03
 Source: Internet
 Author: User

Tags

human embryo development

exosomes treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

*For medical professionals only

The clinical phenotype of PsA is complex and diverse, and personalized treatment recommendations
should be given for different clinical features of patients.

The medical community specially invited two experts, Professor Zhang Liyun and Professor Zhang Fengxiao, to discuss the progress of PsA diagnosis and treatment and the update of the guidelines, and extract the essence for the readers
.

Learn about PsA typing,

Personalized treatment of diseases is valued

Professor Zhang Liyun

Doctor of Medicine, postdoctoral supervisor
Visiting Scholar, University of Pennsylvania, USA
Vice President of Shanxi Bethune Hospital
Director of the Office of the Clinical Trial Administration (GCP) Institution
Shanxi Bethune Hospital rheumatology immunology academic leader Shanxi Province famous doctor

As the name suggests, PsA is strongly associated with psoriasis, but not all patients begin with lesions, and lesions and arthritis are not parallel
.

IL-17 inhibitors comprehensively cover PsA treatment pain points

Professor Zhang Fengxiao

Chief physician/professor, master supervisor
He is a well-known expert of Hebei Provincial People's Hospital, the founder and discipline leader of rheumatology and immunology
He is the chairman of the Rheumatology and Immunology Branch of Hebei Medical Doctor Association
Former Chairman of the Rheumatology Branch of Hebei Medical Association
He is a member of the Rheumatology Branch of the Chinese Medical Association

IL-17A is a member of the cytokine IL-17 superfamily and plays an important role in the development of skin lesions, arthritis, and enthesitis of PsA, and induces pathological bone resorption by directly activating osteoclast precursors, leading to joint ^{malformations[3].

PsA is a highly heterogeneous disease with a variety of clinical manifestations, and different clinical phenotypes, non-musculoskeletal manifestations, and comorbidities may affect drug use and efficacy, and systematic evaluation is critical
to the treatment options of PsA.

The advent of biologics has brought landmark changes
to the treatment of PsA.

Clinical studies have shown that the treatment of PsA by scuchizumab can effectively improve the typical clinical symptoms of PsA, and effectively delay radiological progression and reduce long-term structural damage
.

Based on rich clinical evidence, authoritative guidelines and diagnostic and treatment specifications at home and abroad have included IL-17 inhibitors in the first-line recommendation
of PsA biologic therapy.

References:[1] Cui Ran, et al.
Journal of Clinical Internal Medicine,2021,(5):301-304.

Gu Jun, et al.
Chinese Journal of Dermatology, 2020(8):585-595.

Su Yin, et al.
Chinese Journal of Internal Medicine, 2022, 61(8): 883-892.

[4]Singh JA,et al.
Arthritis Care Res (Hoboken).
2019 Jan; 71(1):2-29.

[5]Gossec L, et al.
Ann Rheum Dis.
2020 Jun; 79(6):700-712.

[6]Coates LC, et al.
Nat Rev Rheumatol.
2022 Aug; 18(8):465-479.

[7]Benavent D,et al.
EULAR 2021.
#AB0741.

[8]Mease P,et al.
Ann Rheum Dis.
2018 Jun; 77(6):890-897.

[9]Baraliakos X,et al.
Ann Rheum Dis.
2021 May; 80(5):582-590.

[10]Mease PJ,et al.
RMD Open.
2021 Jul; 7(2):e001600.

[11]Nash P, et al.
Clin Exp Rheumatol.
2022 May; 40(5):952-959.
This article is intended solely for the purpose of providing scientific information to healthcare professionals and does not represent the position of the
Platform.}

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.